Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N.

Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.

2.

Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours.

Izquierdo E, Yuan L, George S, Hubank M, Jones C, Proszek P, Shipley J, Gatz SA, Stinson C, Moore AS, Clifford SC, Hicks D, Lindsey JC, Hill RM, Jacques TS, Chalker J, Thway K, O'Connor S, Marshall L, Moreno L, Pearson A, Chesler L, Walker BA, De Castro DG.

Oncotarget. 2017 Dec 6;8(67):112036-112050. doi: 10.18632/oncotarget.23000. eCollection 2017 Dec 19.

3.

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG.

Semin Oncol. 2017 Jun;44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. Epub 2017 Sep 15. Review.

4.

Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.

Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, Fenwick SW, Halloran SP, Hochhauser D, Hull MA, Koelzer VH, McNair AGK, Monahan KJ, Näthke I, Norton C, Novelli MR, Steele RJC, Thomas AL, Wilde LM, Wilson RH, Tomlinson I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative.

Gut. 2018 Jan;67(1):179-193. doi: 10.1136/gutjnl-2017-315333. Review.

5.

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.

Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, Röthlisberger B, Ludin K, Merkelbach-Bruse S, Heydt C, Ligtenberg MJL, Mensenkamp AR, de Castro DG, Jones T, Vivancos A, Kondrashova O, Pauwels P, Weyn C, Hahnen E, Hauke J, Soong R, Lai Z, Dougherty B, Carr TH, Johnson J, Mills J, Barrett JC.

Hum Mutat. 2018 Mar;39(3):394-405. doi: 10.1002/humu.23375. Epub 2017 Dec 28.

6.

Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma.

Lee JY, Garcia-Murillas I, Cutts RJ, De Castro DG, Grove L, Hurley T, Wang F, Nutting C, Newbold K, Harrington K, Turner N, Bhide S.

Br J Cancer. 2017 Sep 5;117(6):876-883. doi: 10.1038/bjc.2017.258. Epub 2017 Aug 15.

7.

The Chemical Profile of Senna velutina Leaves and Their Antioxidant and Cytotoxic Effects.

Campos JF, de Castro DT, Damião MJ, Vieira Torquato HF, Paredes-Gamero EJ, Carollo CA, Estevinho LM, de Picoli Souza K, Dos Santos EL.

Oxid Med Cell Longev. 2016;2016:8405957. Epub 2016 Oct 10.

8.

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.

Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, Swanton C.

Lancet. 2016 Sep 3;388(10048):1002-11. doi: 10.1016/S0140-6736(16)31340-X. Epub 2016 Sep 1. Review.

PMID:
27598680
9.

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N.

Carcinogenesis. 2016 Sep;37(9):852-7. doi: 10.1093/carcin/bgw073. Epub 2016 Jul 5.

10.

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.

Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC.

Clin Cancer Res. 2015 Sep 15;21(18):4174-4183. doi: 10.1158/1078-0432.CCR-14-2759. Epub 2015 Mar 16.

11.

Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial.

Kapp JR, Diss T, Spicer J, Gandy M, Schrijver I, Jennings LJ, Li MM, Tsongalis GJ, de Castro DG, Bridge JA, Wallace A, Deignan JL, Hing S, Butler R, Verghese E, Latham GJ, Hamoudi RA.

J Clin Pathol. 2015 Feb;68(2):111-8. doi: 10.1136/jclinpath-2014-202644. Epub 2014 Nov 27.

12.

A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.

Le Quesne J, Maurya M, Yancheva SG, O'Brien M, Popat S, Wotherspoon AC, de Castro DG, Nicholson AG.

J Thorac Oncol. 2014 Jun;9(6):769-74. doi: 10.1097/JTO.0000000000000157.

13.

Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.

Deans ZC, Bilbe N, O'Sullivan B, Lazarou LP, de Castro DG, Parry S, Dodson A, Taniere P, Clark C, Butler R.

J Clin Pathol. 2013 Apr;66(4):319-25. doi: 10.1136/jclinpath-2012-201227. Epub 2013 Feb 1.

PMID:
23378269
14.

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.

Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ, de Castro DG.

PLoS One. 2013;8(1):e53733. doi: 10.1371/journal.pone.0053733. Epub 2013 Jan 10.

15.

Multipath estimation in urban environments from joint GNSS receivers and LiDAR sensors.

Ali K, Chen X, Dovis F, De Castro D, Fernández AJ.

Sensors (Basel). 2012 Oct 30;12(11):14592-603. doi: 10.3390/s121114592.

16.

Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.

Stemke-Hale K, Shipman K, Kitsou-Mylona I, de Castro DG, Hird V, Brown R, Flanagan J, Gabra H, Mills GB, Agarwal R, El-Bahrawy M.

Mod Pathol. 2013 Apr;26(4):544-52. doi: 10.1038/modpathol.2012.194. Epub 2012 Nov 23.

17.

Challenges for the implementation of routine molecular diagnostics in cancer care.

de Castro DG.

Expert Rev Mol Diagn. 2011 Jul;11(6):549-51. doi: 10.1586/erm.11.37. No abstract available.

PMID:
21745007
18.

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.

Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, de Castro DG, Austin S, Awan A, Burt E, Clench T, Farruggia J, Hancock J, Irvine AE, Kizilors A, Langabeer S, Milner BJ, Nickless G, Schuh A, Sproul A, Wang L, Wickham C, Cross NC.

Br J Haematol. 2011 Apr;153(2):179-90. doi: 10.1111/j.1365-2141.2011.08603.x. Epub 2011 Mar 8.

PMID:
21382019
19.

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.

Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R; European EGFR Workshop Group.

J Thorac Oncol. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de.

20.

Immunologically silent cancer clone transmission from mother to offspring.

Isoda T, Ford AM, Tomizawa D, van Delft FW, De Castro DG, Mitsuiki N, Score J, Taki T, Morio T, Takagi M, Saji H, Greaves M, Mizutani S.

Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17882-5. doi: 10.1073/pnas.0904658106. Epub 2009 Oct 12.

Supplemental Content

Loading ...
Support Center